APX001 is Effective Treatment for Murine Coccidioidomycosis

ASM Microbe 2018

Pharmacokinetics/pharmacodynamics (PK/PD) of the novel, first-in-class glycosylphosphatidylinositol (GPI) Inhibitor APX001 in the neutropenic murine invasive candidiasis model against C. albicans (CA), C. glabrata, and C. auris (CAU)

ECCMID 2018

Candida auris is highly in vitro susceptible to APX001A in EUCAST antifungal susceptibility testing

ECCMID 2018

EUCAST susceptibility testing of APX001A: MIC Data for Contemporary Clinical Blood Stream Isolates

TIMM 2017

Isolation of APX001A Resistant Strains and Characterization of Underlying Mechanisms in Candida spp.

ASM 2017

Pharmacodynamics of the active moiety APX001A in human pulmonary and nasal in vitro models of invasive aspergillosis

ECCMID 2017

EUCAST susceptibility testing of APX001A: Impact of choice of microtitre plate type, dilution method and plate storage

ECCMID 2017

In vitro activity of APX001A and comparators against clinical isolates of rare moulds

ECCMID 2017

Efficacy of APX001 in a Murine Model of Cryptococcal Meningitis

ID Week 2017

Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis

ID Week 2017

Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A

ID Week 2017

Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris

ID Week 2017

APX001 Protects Immunosuppressed Mice from Rhizopus delemar Infection

ID Week 2017

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001A Bioavailability

ID Week 2017

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

ID Week 2017

Absorption, Distribution, and Excretion of [14C]-APX001 after Single-Dose Administration to Rats and Monkeys

ID Week 2017

The Investigational Agent E1210 is Effective for the Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans

ICAAC 2014

In Vitro Activity of E1210 and In Vivo Activity of E1211, a Water-Soluble Prodrug of E1210, in Combination with Other Antifungals

ICAAC 2011

Physicochemical properties and Nonclinical Pharmacokinetics of E1211, a Water-Soluble Prodrug of E1210

ICAAC 2011

In Vitro and In Vivo Antifungal Activities of E1211, a Water-Soluble Prodrug of E1210

ICAAC 2011

In Vitro Activity of a Novel Broad-spectrum Antifungal Agent, E1210, and Comparators Tested against Candida spp.

ICAAC 2011

In Vitro Activity of a Novel Broad-spectrum Antifungal, E1210, Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution (BMD) Methods

ICAAC 2011

Pre-clinical Development of Susceptibility Testing Methods for the Novel Antifungal E1210 Tested against Candida: Comparison of CLSI and EUCAST Methods

ICAAC 2011

Preclinical Pharmacokinetics and Toxicology of E1210, a New Broad-Spectrum Antifungal

ICAAC 2010

In Vivo Pharmacodynamic Correlates of Success for E1210 Treatment of Disseminated Candidiasis

ICAAC 2010

Efficacy of Oral E1210, a New Broad-Spectrum Antifungal, in Murine Models of Oropharyngeal Candidiasis, Disseminated Candidiasis, and Pulmonary Aspergillosis

ICAAC 2010

E1210, a New Broad-Spectrum Antifungal, Inhibits Glycosylphosphatidylinositol Biosynthesis in Fungi and Affects Candida albicans Cell Characteristics

ICAAC 2010

* = submitted